Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Mylan

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Mylan's 2012 sales performance.

Mylan Inc.

Generic Differentiation

Generic Differentiation

lucrative. The latter is what we see when companies like Mylan or Teva copy good but aged small molecules.

NHS says Humira biosimilar deal will save £300m

NHS says Humira biosimilar deal will save £300m s Cyltezo and Mylan’s Hulio, the latter sublicensed from Japan’s Fujifilm Kyowa Kirin. ... NHS England says it has accepted bids from four companies – Amgen, Biogen, Mylan and Sandoz – as well as AbbVie.

Generic threat looms to J&J’s blockbuster Zytiga in US

Generic threat looms to J&J’s blockbuster Zytiga in US Generic drugmakers that have already won approval for generic Zytiga from the FDA include Mylan, Teva and Hikma Pharma and – with the injunction denied – there is nothing to stop them from

Deal Watch October 2018

Mylan has enhanced its respiratory portfolio with the acquisition of Novartis’s TOBI Podhaler and TOBI solution, both products for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. ... Licensing &. research. collaboration. $550m.

Amgen CEO says Aimovig is “one of most successful launches”

Amgen CEO says Aimovig is “one of most successful launches” of weakness from biosimilar competition after Mylan/Biocon launched their Fulphila rival in July.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics